| Similar Articles |
|---|
 |
The Motley Fool
May 21, 2009
Selena Maranjian |
Make Money With or Without Health-Care Reform While there's obviously a lot at stake in the health-care discussions going on in Washington, you don't have to guess right about what's going to happen in order to profit from the industry.   |
The Motley Fool
January 20, 2010
Brian Orelli |
Health-Care Reform: It's Not Over Yet Massachusetts has spoken with its election of Scott Brown to the Senate. What's up next? |
The Motley Fool
June 22, 2010 |
UnitedHealth and Wellpoint: Looking Good for the Long Term There are two big players -- UnitedHealth Group and WellPoint -- that are still trading at historical lows. |
The Motley Fool
November 8, 2011
Brian Wilson |
2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues. |
The Motley Fool
July 17, 2008
Brian Orelli |
Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release |
The Motley Fool
January 20, 2009
Brian Orelli |
Johnson & Johnson Nimble ... for Now The health-care giant reports increasing earnings, despite falling revenue. |
The Motley Fool
February 2, 2010
Dan Caplinger |
You Can't Afford This Huge Mistake If you start trading frequently instead of investing for the long run, you'll end up costing yourself a lot more than you may think -- and you'll dig yourself so deep a hole that you may never get out. |
BusinessWeek
January 20, 2010
Albert R. Hunt |
The Democrats' Long Road Back from Massachusetts After Republican Scott Brown's stunning upset, the best President Obama and his party can hope for may be a watered-down health bill with insurance reforms. |
The Motley Fool
February 26, 2010
Brian Orelli |
Political Theater: More Entertaining Than Helpful Health-care reform, like health-care stocks, remains still stuck in limbo. |
The Motley Fool
January 25, 2011
Eric Dutram |
Tuesday's ETF to Watch: iShares Dow Jones U.S. Health Care Index Fund (IYH) The health-care sector has stagnated in recent weeks -- what does that mean for these ETFs? |
The Motley Fool
August 24, 2010
Brian Orelli |
One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well. |
The Motley Fool
July 14, 2008
Brian Orelli |
Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut? |
The Motley Fool
April 22, 2009
Selena Maranjian |
Will Health-Care Reform Hurt Investors? The bad news here is that there's quite a bit of uncertainty around this issue, and that some health-care-focused companies may end up suffering. Read on to see who. |
The Motley Fool
January 28, 2010
Brian Orelli |
Health-Care Reform Is Dead. Probably. Breaking up the bill doesn't seem like the answer. What do insurers and pharmaceutical companies have to say? |
The Motley Fool
August 27, 2010
Brian Orelli |
A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much. |
The Motley Fool
November 22, 2011
Selena Maranjian |
Make Money in Global Health-Care Stocks the Easy Way If you expect the global health-care industry to thrive as our planet's population grows and ages, the iShares S&P Global Health Care ETF could save you a lot of trouble. |
The Motley Fool
February 28, 2011
David Williamson |
Don't Miss These Health-Care ETFs Two ways ETFs can help your portfolio |
The Motley Fool
July 20, 2010
Brian Orelli |
Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant. |
The Motley Fool
June 14, 2011
Selena Maranjian |
Make Money in Health Care the Easy Way There's no need to guess which health-care company will perform best when you invest in the Vanguard Health Care ETF. |
The Motley Fool
August 12, 2011
Selena Maranjian |
Make Money in Health-Care Companies the Easy Way There's no need to guess which health-care company will perform best. A well-chosen ETF can grant you instant diversification across the industry -- and make investing in and profiting from its companies that much easier. |
The Motley Fool
October 5, 2009
Dan Caplinger |
Where the Real Value Is Now Here's a sample of stocks that look relatively cheap compared with their peers and the overall market: Chevron... Oracle... FMC... Raytheon... Kraft Foods... |
The Motley Fool
January 18, 2011
Russ Krull |
Keep It or Sweep It: Johnson & Johnson? Should the company be held or sold? |
The Motley Fool
December 9, 2011
Paul Chi |
3 Europe-Proof Stocks for Your Portfolio These health-care stocks are Europe-proof. |
The Motley Fool
September 3, 2009
Brian Orelli |
Now That's How to Grow a Company! Dear Pfizer and Merck, you really should take note of how Abbott Labs is growing. |
The Motley Fool
January 17, 2012
Brian Orelli |
Pharma Focus Is Good For Your Portfolio Build your own portfolio. |
The Motley Fool
December 24, 2009
Brian Orelli |
Health-Care Reform: Two-Thirds Finished The U.S. Senate voted this morning to pass the health-care reform bill, moving us closer to capping off the long process that's weighed on health-care and insurance stocks this year. |
The Motley Fool
May 12, 2010
Matt Koppenheffer |
Are Health-Care Stocks a Buy? Health-care stocks have underperformed the market so far this year. Is it time for a turnaround? |
The Motley Fool
February 24, 2009
Brian Orelli |
Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success. |
The Motley Fool
December 3, 2009
Brian Orelli |
Health-Care Reform Is Very Taxing On the industries that keep us alive. |
The Motley Fool
October 15, 2008
Brian Orelli |
Abbott's Stents Aren't (That) Important Abbott's shareholders shouldn't be too focused on drug-eluting stents. |
The Motley Fool
September 30, 2009
Dave Mock |
Health-Care Stocks Obama Would Buy This up-and-coming sector could play a big role in reform, especially for companies that bring new efficiencies to health care. |
The Motley Fool
November 15, 2011
Dan Caplinger |
Has Abbott Labs Become the Perfect Stock? For long-term investors, Abbott's continuing devotion to up its dividend -- its streak now stands at 39 years -- makes a compelling reason to hold onto your shares. |
The Motley Fool
February 25, 2010
Brian Orelli |
Weekly Walk of Shame: Partisan Posturing on Health-Care Reform Our portfolios may not like it, but our pocketbooks need health-care reform. |
The Motley Fool
June 15, 2011
Brian Orelli |
Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market. |
The Motley Fool
January 5, 2009
Matt Hoffman |
Is Buy and Hold Dead? Are you an investor or a speculator? Read on to see. |
The Motley Fool
June 4, 2010
Brian Orelli |
Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other. |
The Motley Fool
November 16, 2009
Amanda B. Kish |
The Hottest Sector for 2010 It's hard to argue that the potential benefits to this sector won't be significant if health care reform does work its way through. The time to stock up on high-quality health-care names is now. |
The Motley Fool
December 9, 2009
Brian Orelli |
Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon. |
The Motley Fool
February 9, 2010
Brian Orelli |
What Bipartisan Health-Care Reform Means for Investors Republicans and Democrats will debate on TV, but little may come of it. |
The Motley Fool
February 24, 2011
Brian Orelli |
Abbott: 1, Johnson & Johnson: 0 -- For Now Abbott Labs got a ruling overturned yesterday that would have cost the company $1.8 billion, yet investors let shares slip down 1%. |
The Motley Fool
July 1, 2010
Alex Dumortier |
3 Stocks and 3 ETFs to Salvage 2010 Investing after a tough first half. |
The Motley Fool
December 18, 2008
Dan Caplinger |
The Wrong Way to Invest Today Avoid the temptation to use volatility for short-term gains. |
The Motley Fool
October 14, 2008
Brian Orelli |
Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace. |
The Motley Fool
August 25, 2009
Jennifer Schonberger |
7 Health-Care Stocks to Nurse Your Portfolio As fears about the health-care bill abate, valuations in the sector look ripe. |
The Motley Fool
September 22, 2008
Zoe Van Schyndel |
ETFs to Keep You Safe Invest selectively and defensively in times of turmoil with these ETFs. |
BusinessWeek
August 6, 2009 |
Health Reform: A Timeline The latest battle over how to overhaul the U.S. health-care system intensified last fall with the election of Barack Obama. |
The Motley Fool
October 14, 2009
Brian Orelli |
Consistency Makes This Stock a Winner Abbott turns in a solid quarter, but it needs to keep branching out. |
The Motley Fool
October 13, 2008
Brian Orelli |
Foolish Forecast: J&J's Diversity Counts Views you can use to get clues on tomorrow's news |
The Motley Fool
January 27, 2010
Brian Orelli |
Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that. |
The Motley Fool
August 19, 2010
Brian Orelli |
Buffett Is Buying J&J. Should You? It depends on your time horizon. |
